Abeona Therapeutics Inc vs Marathon Digital Holdings Inc — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $421.19M), while Marathon Digital Holdings Inc trades at $9.64 (market cap $3.74B). The key difference: Marathon Digital Holdings Inc is far larger — about 8.9× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Marathon Digital Holdings Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | MARA | |
|---|---|---|
Market Cap | $421.19M | $3.74B |
Sector | Health | Technology |
52-Week High | $7.45 | $22.84 |
52-Week Low | $4.17 | $6.73 |
Enterprise Value | $276.10M | $5.78B |
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.46, up 0.13% with strong technical momentum as moving averages signal bullish sentiment. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent positive developments include CMS granting NTAP status for ZEVASKYN and expanding treatment centers, while consistently beating earnings expectations.
Outlook remains positive with analyst consensus at 66.7% buy ratings, but risks include shareholder investigation and high RSI levels suggesting overbought conditions. The stock's valuation appears reasonable with P/E of 7.78, though negative operating cash flow requires monitoring as the company scales commercialization efforts.
MARA Holdings trades at $9.64, down 6% post-Q2 2026 results, with a bearish technical signal and negative earnings trends. The company reported a net loss of $1.31 billion in 2025, with revenue declining to $804 million in 2026. Recent news highlights a strategic pivot to AI infrastructure, but investor sentiment remains cautious amid Bitcoin mining sector weakness.
Outlook is mixed: analyst consensus targets $16.08 (67% upside), but high losses and sector volatility pose risks. The AI transition offers growth potential, yet execution challenges and persistent negative margins demand caution. Near-term pressure from missed earnings and competitive threats may limit upside.
Trailing returns across standard periods
Latest headlines on both assets
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →Marathon Digital Holdings, Inc. is one of the largest publicly traded Bitcoin mining companies in North America. The company focuses on building and operating large-scale, cost-efficient Bitcoin mining facilities. Marathon's strategy centers on increasing its mining hash rate and using sustainable energy sources to expand its Bitcoin production. The company's performance is closely tied to the price of Bitcoin and the overall health of the digital asset mining industry.
Read more on MARA →